Literature DB >> 16388408

Transport kinetics of iron chelators and their chelates in Caco-2 cells.

Xi-Ping Huang1, M Spino, J J Thiessen.   

Abstract

PURPOSE: Caco-2 monolayers were used to contrast the bidirectional transport of iron chelators and their chelates and to estimate fundamental kinetics associated with their intestinal absorption.
METHODS: Bidirectional transport was studied at 37 degrees C and pH 7.4 using 500-microM concentrations. Monolayer integrity was tested via transepithelial electrical resistance and sodium fluorescein permeability. Apical and basolateral analysis provided mass balance evidence. Apparent permeability coefficient (P(app)) served to rank and compare molecules and estimate in vivo bioavailability. Model-dependent rate constants defined cellular influx and efflux.
RESULTS: 1) P(app) ranked in decreasing order for chelators from directional transport studies were CP363 > deferiprone> ICL670 > CP502 > deferoxamine (DFO). 2) Fe(CP502)(3), Fe(ICL670)(2), and FeDFO were not measurable in receiving chambers, whereas Fe(deferiprone)(3) and Fe(CP363)(3) were detected in both directions. 3) CP363 was transported significantly faster from the basolateral to the apical direction than the converse. 4) Mass balance of donor and receiver chambers gave approximately 100% recovery in all cases. 5) Kinetic analysis supports the view that the Caco-2 chelator efflux constants are generally greater than their influx constants.
CONCLUSIONS: Caco-2 cells are useful in screening iron chelators and chelates and estimating bioavailabilities. Structure and distribution coefficients partially predict passive transport through Caco-2 monolayers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16388408     DOI: 10.1007/s11095-005-9258-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: correlation with physico-chemical properties and oral activity.

Authors:  N Lowther; R Fox; B Faller; H Nick; Y Jin; T Sergejew; Y Hirschberg; R Oberle; H Donnelly
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

2.  Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs.

Authors:  Duxin Sun; Hans Lennernas; Lynda S Welage; Jeffery L Barnett; Christopher P Landowski; David Foster; David Fleisher; Kyung-Dall Lee; Gordon L Amidon
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

3.  Caco-2 cell permeability of a new (hydroxybenzyl)ethylenediamine oral iron chelator: correlation with physicochemical properties and oral activity.

Authors:  N Lowther; B Tomlinson; R Fox; B Faller; T Sergejew; H Donnelly
Journal:  J Pharm Sci       Date:  1998-09       Impact factor: 3.534

4.  Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells.

Authors:  P Artursson; J Karlsson
Journal:  Biochem Biophys Res Commun       Date:  1991-03-29       Impact factor: 3.575

5.  The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.

Authors:  Adriana Ceci; Paola Baiardi; Mariagrazia Felisi; Maria Domenica Cappellini; Vittorio Carnelli; Vincenzo De Sanctis; Renzo Galanello; Aurelio Maggio; Giuseppe Masera; Antonio Piga; Francesco Schettini; Ippazio Stefàno; Fernando Tricta
Journal:  Br J Haematol       Date:  2002-07       Impact factor: 6.998

6.  pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions.

Authors:  Sibylle Neuhoff; Anna-Lena Ungell; Ismael Zamora; Per Artursson
Journal:  Pharm Res       Date:  2003-08       Impact factor: 4.200

7.  The Caco-2 cell culture system can be used as a model to study food iron availability.

Authors:  M N Garcia; C Flowers; J D Cook
Journal:  J Nutr       Date:  1996-01       Impact factor: 4.798

8.  Role of redox systems on Fe3+ uptake by transformed human intestinal epithelial (Caco-2) cells.

Authors:  M T Núñez; X Alvarez; M Smith; V Tapia; J Glass
Journal:  Am J Physiol       Date:  1994-12

9.  Iron absorption by CaCo 2 cells cultivated in serum-free medium as in vitro model of the human intestinal epithelial barrier.

Authors:  C Halleux; Y J Schneider
Journal:  J Cell Physiol       Date:  1994-01       Impact factor: 6.384

10.  The transport of two iron chelators, desferrioxamine B and L1, across Caco-2 monolayers.

Authors:  K O Hamilton; L Stallibrass; I Hassan; Y Jin; C Halleux; M Mackay
Journal:  Br J Haematol       Date:  1994-04       Impact factor: 6.998

View more
  9 in total

1.  Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy.

Authors:  Xi-Ping Huang; Jake J Thiessen; Michael Spino; Douglas M Templeton
Journal:  Int J Hematol       Date:  2010-03-09       Impact factor: 2.490

2.  Restored iron transport by a small molecule promotes absorption and hemoglobinization in animals.

Authors:  Anthony S Grillo; Anna M SantaMaria; Martin D Kafina; Alexander G Cioffi; Nicholas C Huston; Murui Han; Young Ah Seo; Yvette Y Yien; Christopher Nardone; Archita V Menon; James Fan; Dillon C Svoboda; Jacob B Anderson; John D Hong; Bruno G Nicolau; Kiran Subedi; Andrew A Gewirth; Marianne Wessling-Resnick; Jonghan Kim; Barry H Paw; Martin D Burke
Journal:  Science       Date:  2017-05-12       Impact factor: 47.728

3.  Design and synthesis of N-hydroxyalkyl substituted deferiprone: a kind of iron chelating agents for Parkinson's disease chelation therapy strategy.

Authors:  Qingchun Zhang; Shufan Feng; Yulian Zhao; Bo Jin; Rufang Peng
Journal:  J Biol Inorg Chem       Date:  2021-05-08       Impact factor: 3.358

4.  Synthesis, Physicochemical Studies, Molecular Dynamics Simulations, and Metal-Ion-Dependent Antiproliferative and Antiangiogenic Properties of Cone ICL670-Substituted Calix[4]arenes.

Authors:  Pascal Rouge; Alexandra Dassonville-Klimpt; Christine Cézard; Stéphanie Boudesocque; Roger Ourouda; Carole Amant; François Gaboriau; Isabelle Forfar; Jean Guillon; Emmanuel Guillon; Enguerran Vanquelef; Piotr Cieplak; François-Yves Dupradeau; Laurent Dupont; Pascal Sonnet
Journal:  Chempluschem       Date:  2012-11-01       Impact factor: 2.863

5.  Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers.

Authors:  Zufan Debebe; Sergei Nekhai; Meseret Ashenafi; David B Lovejoy; Danuta S Kalinowski; Victor R Gordeuk; W Malcolm Byrnes; Des R Richardson; Pradeep K Karla
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-08-15       Impact factor: 3.205

6.  In vitro studies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics.

Authors:  Axel Steinbrueck; Adam C Sedgwick; Hai-Hao Han; Michael Y Zhao; Sajal Sen; Dan-Ying Huang; Yi Zang; Jia Li; Xiao-Peng He; Jonathan L Sessler
Journal:  Chem Commun (Camb)       Date:  2021-06-08       Impact factor: 6.065

Review 7.  The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary-Ironing out the Brain.

Authors:  Robert R Crichton; Roberta J Ward; Robert C Hider
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-17

8.  Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial.

Authors:  Deepti Saxena; Michael Spino; Fernando Tricta; John Connelly; Bernadette M Cracchiolo; Axel-Rainer Hanauske; Darlene D'Alliessi Gandolfi; Michael B Mathews; Jonathan Karn; Bart Holland; Myung Hee Park; Tsafi Pe'ery; Paul E Palumbo; Hartmut M Hanauske-Abel
Journal:  PLoS One       Date:  2016-05-18       Impact factor: 3.240

Review 9.  Is Chelation Therapy a Potential Treatment for Parkinson's Disease?

Authors:  Roberta J Ward; David T Dexter; Antonio Martin-Bastida; Robert R Crichton
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.